HIV, Flu & HBV/HCV Focus of Antiviral Drug Discovery Conference on March 15-16, 2000, in New Jersey

Princeton, New Jersey (PROTEXT) - Pharmaceutical industry advances in the discovery and development of novel antiviral agents in HIV, influenza/respiratory, and hepatitis B & C, will be presented in depth on March 15-16, 2000 at the Hyatt Regency Hotel in Princeton, NJ, announces Strategic Research Institute. The conference will feature work in the neuraminidase inhibitor area presented by Roche (Tamiflu), Glaxo Wellcome (Relenza), and RW Johnson PRI (RWJ-270201), Agouron's protease inhibitor for rhinovirus infection, and clinical summary of ViroPharma's Pleconaril, a novel therapy for picornaviral disease. In HIV, the conferences focuses on Trimeris' fusion inhibitor, T-20 and Merck's Integrase inhibitor; also featured will be reverse transcriptase inhibitors, plus contributions from other companies. The HBV/HCV section will feature discussion of Schering Plough's Ribavirin, Roche's Pegainterferon alfa-2a and contributions from Eli Lilly and Glaxo Wellcome; Emory University and Novirio Pharmaceuticals will present new data on nucleoside analogs and L-nucleosides, both having shown potent activity against hepatitis B. To request the agenda and/or register, please contact Camille Coward of Strategic Research at ccoward@srinstitute.com or by phone at 212-967-0095, ext 255. ots Original Text Service: Strategic Research Institute Internet: http://www.newsaktuell.de Contact: Camille Coward of Strategic Research, ccoward@srinstitute.com, (USA) 212-967-0095, ext 255 Web site: http://www.srinstitute.com Subscribers please note that material bearing the slug "PROTEXT" is not part of CTK's news service and is not to be published under the "CTK" slug. Protext is a commercial service providing distribution of press releases from clients, who are identified in the text of Protext reports and who bear full responsibility for their contents. PROTEXT